Showing 6441-6450 of 7749 results for "".
- Lack of Options for Darker Skin Types Hinder Use of Tinted Sunscreenshttps://practicaldermatology.com/news/tinted-sunscreens-lack-options-for-darker-skin-hindering-use/2461156/The lack of tinted sunscreen options for darker skin tones may discourage many people from using these products. This is the main message from a new analysis of consumer preferences of over-the-counter tinted sunscreen products. Sixty-two percent of tinted sunscreen products are only av
- Blueberry Extract May Improve Wound Healinghttps://practicaldermatology.com/news/blueberry-extract-may-improve-wound-healing/2461152/Treating wounds with an extract taken from wild blueberries may improve healing, according to a new study presented at the American Physiological Society’s annual meeting at Experimental Biology 2022. Researchers from the University of Maine previously found that a phenolic extrac
- Dermatological Society of New Jersey Kicks Off Virtual Conference Saturdayhttps://practicaldermatology.com/news/dermatological-society-of-new-jersey-kicks-off-virtual-conference-saturday/2461147/The DSNJ annual educational conference is a hybrid event this year, with in person as well as online conference experiences open to attendees across the US. The conference is Saturday, April 9. Penn Medicine Princeton Health, accredited by the Medical Society of New Jersey, designa
- Practical Dermatology® Names New Interim Digital Practice Editorhttps://practicaldermatology.com/news/practical-dermatology-names-new-interim-digital-practice-editor/2461145/Practical Dermatology® magazine is proud to announce that Vishal Anil Patel, MD will serve as interim editor of our Digital Practice column. Dr. Patel is director of cutaneous oncology at GW Cancer Center, director of dermatologic surgery at GW department of der
- Boehringer Ingelheim’s Effisayil Offers Sustained Relief from GPP Flareshttps://practicaldermatology.com/news/boehringer-ingelheims-effisayil-offers-sustained-releif-from-gpp-flares/2461143/Effisayil (Spesolimab) clears skin pustules in patients with generalized pustular psoriasis (GPP) flares within the first week after treatment, and these benefits are sustained over 12 weeks, according to data presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Bost
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Opzelura Shows Benefit in 52-Week Phase 3 Vitiligo Studyhttps://practicaldermatology.com/news/opzelura-shows-benefit-in-52-week-phase-3-vitiligo-study/2461139/New 52-week results from the pivotal Phase 3 TRuE-V clinical trial program evaluating Incyte's topical JAK1/JAK2 inhibitor ruxolitinib cream (Opzelura™) in adolescent and adult patients with nonsegmental vitiligo show that twice daily application was
- Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis/2461137/UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, MA, including a late breaking oral platform presentation and 10 posters. The platform presentation details new
- Dupixent Performs Well in Phase 3s for Prurigo Nodularishttps://practicaldermatology.com/news/dupixent-performs-well-in-phase-3s-for-prurigo-nodularis/2461138/Detailed positive results from the Phase 3 PRIME2 trial show Dupixent® (dupilumab) significantly reduced itch and skin lesions compared to placebo in adults with uncontrolled prurigo nodularis. Findings were presented in a late-breaking session at the American Academy of Dermat
- Galderma Launches Twyneo in the UShttps://practicaldermatology.com/news/galderma-launches-twyneo-in-the-us/2461128/Galderma has launched Twyneo (tretinoin and benzoyl peroxide) Cream, 0.1%/3% in the US. The launch takes place during the annual meeting of the American Academy of Dermatology (AAD) Annual Meeting. Twyneo Cream features patented microencapsulation technology t